Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1.
Intravenous administration of liposome-encapsulated hemoglobin (LEH) in rats led to an early (within 15 min) decline of hemolytic complement (C) activity in the plasma along with a significant, parallel rise in thromboxane B2 (TXB2) levels. The TXB2 response was inhibited by co-administration of soluble C receptor type 1 (sCR1) with LEH, as well as by C depletion with cobra venom factor. These observations provide evidence for a causal relationship between LEH-induced C activation and TXB2 release, and suggest that sCR1 could be useful in attenuating the acute respiratory, hematological and hemodynamic side effects of LEH described earlier in the rat.
Szebeni
J
J
Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA.
Spielberg
H
H
Cliff
R O
RO
Wassef
N M
NM
Rudolph
A S
AS
Alving
C R
CR
D000818:Animals; D001802:Blood Substitutes / Q000008:administration & dosage / Q000494:pharmacology; D003167:Complement Activation / Q000187:drug effects*; D003169:Complement Inactivator Proteins / Q000502:physiology*; D004357:Drug Synergism; D005260:Female; D006454:Hemoglobins / Q000008:administration & dosage / Q000494:pharmacology*; D007275:Injections, Intravenous; D008081:Liposomes / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011951:Receptors, Complement / Q000502:physiology*; D013929:Thromboxane B2 / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism*
D001802:Blood Substitutes; D003169:Complement Inactivator Proteins; D006454:Hemoglobins; D008081:Liposomes; D011951:Receptors, Complement; D013929:Thromboxane B2